Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02

Armata Pharmaceuticals, Inc.

• Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.
• FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.
• FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.
• cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.
• Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.